A good example of this is the ZEPHIR trial 86, which was able to characterize tumour and therapy heterogeneity on the patient and tumour scale, based on pre-treatment HER2-PET/CT with 89Zr-trastuzumab and FDG-PET/CT after just one treatment cycle. The gene discussed is ERBB2; the disease is neoplasm.